Narimatsu Hiroto, Kami Masahiro
Division of The Strategic Outcome Research Program for Cancer Control MHLW-commission, Japan Cancer Society, Yurakucho Center Bldg. (Mullion) 13F, 2-5-1, Yurakucho Chiyoda-ku Tokyo, 100-0006, Japan.
Expert Rev Anti Infect Ther. 2008 Jun;6(3):373-84. doi: 10.1586/14787210.6.3.373.
Fungal infection remains an important complication in allogeneic stem cell transplantation (allo-SCT). Since the prognosis of fungal infection is poor, prophylaxis is critical for its management; owing to recent progression in allo-SCT management and widespread use of reduced-intensity regimens, the strategy of infectious prophylaxis has also changed. Various antifungals have recently been developed and applied to clinical use. A major change in antifungal management will probably occur in the next few years.
真菌感染仍是异基因造血干细胞移植(allo-SCT)中的一个重要并发症。由于真菌感染的预后较差,预防对于其治疗至关重要;鉴于allo-SCT治疗的最新进展以及低强度方案的广泛应用,感染预防策略也发生了变化。各种抗真菌药物最近已被研发并应用于临床。抗真菌治疗的一个重大变革可能会在未来几年发生。